The aim of this study was to explore the nasal route as an alternative to daily subcutaneous injections of hPTH (1-34). Anesthetized rats were surgically prepared and nasally dosed with aqueous solutions of hPTH (1-34). Plasma samples were assayed by radioimmunoassay and data generated fit to two- (intravenous) and one- (intranasal) compartment pharmacokinetic models using WinNonlin®. The toxicity of hPTH (1-34) solution administered to the rats was assessed by screening its effect on transepithelial electrical resistance, potential difference, paracellular marker permeation, tissue viability, and protein leakage using the EpiAirway® tissue model. The intranasal absorption of hPTH (1-34) was rapid; the absorption rate constants () were 33.2 ± 24 h^{- 1} [without bovine serum albumin (BSA)] and 9.8 ± 5.1 h^{- 1} (with 1% BSA). The maximum plasma concentrations (C_max): 151 ± 24 pg/mL (without BSA) and 176 ± 37 (with 1% BSA) were attained within approximately 15 min. The intranasal bioavailabilities (F_abs) were 12.1 ± 3.4% (without BSA) and 17.6 ± 1.5% (with 1% BSA). The hPTH (1-34) formulation administered to the rats had no detrimental effect on the EpiAirway® tissue epithelial electrical parameters and functional integrity. Based on the results of this study, the nasal route appears to be a prospective alternative to subcutaneous injections of hPTH (1-34).